Daniel A. Vaena
About
Daniel A. Vaena is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Daniel A. Vaena has authored 68 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 24 papers in Cancer Research. Recurrent topics in Daniel A. Vaena's work include Cancer Genomics and Diagnostics (19 papers), Renal cell carcinoma treatment (16 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Daniel A. Vaena is often cited by papers focused on Cancer Genomics and Diagnostics (19 papers), Renal cell carcinoma treatment (16 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Daniel A. Vaena collaborates with scholars based in United States, Italy and Spain. Daniel A. Vaena's co-authors include Sergio Bracarda, Arlene O. Siefker‐Radtke, Sumanta K. Pal, Elizabeth R. Plimack, Marc‐Oliver Grimm, Ari David Baron, Alexandre Lambert, Alex Azrilevich, Padmanee Sharma and Abdel Saci and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
In The Last Decade
Daniel A. Vaena
63 papers receiving 2.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel A. Vaena United States | 15 | 1.5k | 1.2k | 1.1k | 1.0k | 652 | 68 | 2.7k | ||
| Thomas Powles United Kingdom | 24 | 2.4k 1.6× | 1.1k 0.9× | 1.9k 1.8× | 649 0.6× | 430 0.7× | 105 | 3.7k | ||
| Yann Vano France | 23 | 1.4k 1.0× | 1.2k 1.0× | 289 0.3× | 770 0.8× | 547 0.8× | 83 | 2.4k | ||
| Alexandre Lambert United States | 12 | 1.8k 1.2× | 702 0.6× | 1.0k 0.9× | 372 0.4× | 251 0.4× | 27 | 2.6k | ||
| József Erfán Hungary | 5 | 1.5k 1.0× | 1.2k 1.0× | 769 0.7× | 614 0.6× | 256 0.4× | 6 | 2.6k | ||
| Ali Golshayan United States | 12 | 1.5k 1.0× | 2.1k 1.8× | 438 0.4× | 1.4k 1.4× | 892 1.4× | 17 | 3.3k | ||
| Christian Poehlein United States | 22 | 2.7k 1.8× | 1.2k 1.0× | 1.6k 1.5× | 559 0.5× | 351 0.5× | 79 | 3.8k | ||
| Tina Cheng Canada | 14 | 1.0k 0.7× | 1.7k 1.4× | 347 0.3× | 1.0k 1.0× | 633 1.0× | 39 | 2.3k | ||
| Zbigniew Nowecki Poland | 26 | 1.6k 1.1× | 1.1k 0.9× | 512 0.5× | 510 0.5× | 370 0.6× | 118 | 2.7k | ||
| Amishi Y. Shah United States | 22 | 725 0.5× | 1.0k 0.8× | 489 0.4× | 674 0.7× | 461 0.7× | 131 | 1.7k | ||
| Ryosuke Okamura Japan | 24 | 1.3k 0.9× | 789 0.7× | 489 0.4× | 557 0.5× | 864 1.3× | 86 | 2.2k |
Countries citing papers authored by Daniel A. Vaena
Since
Specialization
Citations
This map shows the geographic impact of Daniel A. Vaena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Vaena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Vaena more than expected).
Fields of papers citing papers by Daniel A. Vaena
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel A. Vaena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Vaena. The network helps show where Daniel A. Vaena may publish in the future.
Co-authorship network of co-authors of Daniel A. Vaena
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Vaena. A scholar is included among the top collaborators of Daniel A. Vaena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Vaena. Daniel A. Vaena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Agarwal, Neeraj, James Brugarolas, Pooja Ghatalia, et al.. (2024). Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Annals of Oncology. 35(12). 1148–1156.
2.
Funt, Samuel A., Petros Grivas, Xīn Gào, et al.. (2024). Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.. Journal of Clinical Oncology. 42(16_suppl). 4575–4575.
3.
Atkins, Michael B., Pooja Ghatalia, Jaime R. Merchan, et al.. (2024). Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.. Journal of Clinical Oncology. 42(16_suppl). 4534–4534.
4.
Stricker, Thomas, Esprit Ma, Elaine Yu, et al.. (2024). Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes. The Oncologist. 29(6). 534–542.
5.
Brugarolas, James, Pooja Ghatalia, S. George, et al.. (2023). 1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. Annals of Oncology. 34. S1011–S1011.
6.
Goldkorn, Amir, Catherine M. Tangen, Melissa Plets, et al.. (2023). Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.. Journal of Clinical Oncology. 41(16_suppl). 5080–5080.
7.
Agarwal, Neeraj, Catherine M. Tangen, Maha Hussain, et al.. (2022). Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Journal of Clinical Oncology. 40(28). 3301–3309.
8.
Elliott, Andrew, Jian Zhang, Qing Zhang, et al.. (2021). Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types. Journal of Molecular Diagnostics. 23(12). 1761–1773.
9.
Garje, Rohan, et al.. (2021). Comprehensive review of chromophobe renal cell carcinoma. Critical Reviews in Oncology/Hematology. 160. 103287–103287.
10.
Figlin, Robert A., Nizar M. Tannir, Robert G. Uzzo, et al.. (2020). Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 26(10). 2327–2336.
11.
Vanderwalde, Ari M., Axel Grothey, Daniel A. Vaena, et al.. (2020). Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. Journal of Personalized Medicine. 10(4). 252–252.
12.
Goldkorn, Amir, Catherine M. Tangen, Melissa Plets, et al.. (2020). Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.. Journal of Clinical Oncology. 38(15_suppl). 5506–5506.
13.
Escudier, Bernard, Thomas Powles, Robert J. Motzer, et al.. (2018). Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology. 36(8). 765–772.
14.
Dawson, Nancy A., Daniel M. Geynisman, Earle F. Burgess, et al.. (2018). Molecular profiles of small cell bladder and prostate cancer and comparisons with small cell lung cancer.. Journal of Clinical Oncology. 36(6_suppl). 264–264.
15.
Sharma, Padmanee, Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 18(3). 312–322.
16.
Galsky, Matt D., Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2016). Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study. Annals of Oncology. 27. vi567–vi567.
17.
Goldkorn, Amir, Melissa Plets, Neeraj Agarwal, et al.. (2016). Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology. 34(15_suppl). 11516–11516.
18.
Mitchell, Darrion, Chad R. Tracy, John M. Buatti, et al.. (2015). Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and Future Directions. Clinical Genitourinary Cancer. 14(1). 12–21.
19.
Delsing, Angela, Linda S. Powers, Daniel A. Vaena, et al.. (2014). Plasma Angiopoietin 2 Concentrations Are Related to Impaired Lung Function and Organ Failure in a Clinical Cohort Receiving High-Dose Interleukin 2 Therapy. Shock. 42(2). 115–120.
20.
Lubaroff, David M., Daniel A. Vaena, James A. Brown, et al.. (2014). Vaccine immunotherapy for prostate cancer: from mice to men. Immunologic Research. 59(1-3). 229–235.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Thomas Powles Breakdown of academic impact, for papers by Yann Vano Breakdown of academic impact, for papers by Alexandre Lambert Breakdown of academic impact, for papers by József Erfán Breakdown of academic impact, for papers by Ali Golshayan Breakdown of academic impact, for papers by Christian Poehlein Breakdown of academic impact, for papers by Tina Cheng Breakdown of academic impact, for papers by Zbigniew Nowecki Breakdown of academic impact, for papers by Amishi Y. Shah Breakdown of academic impact, for papers by Ryosuke Okamura